KMT2A Antibody

1. our work shows that ALOX5 plays a moderate anti-tumor role and functions as a drug sensitizer, with a therapeutic potential, in MLL-rearranged AML. PMID: 28500307
2. Studied lysine methyltransferase 2A (KMT2A) genetic rearrangements in child and young adult T-lymphoblastic leukemia/lymphoma. PMID: 30203571
3. Our experience suggests that AML with KMT2A rearrangement should be considered for the differential diagnosis of infantile cases with atypical monocytosis suggestive of JMML. Cytogenetic studies, including fluorescence in situ hybridization analysis of KMT2A, may be helpful in distinguishing between AML with KMT2A rearrangement and JMML. PMID: 30143999
4. Replication stress-induced recruitment of EndoG to the MLLbcr. PMID: 28626219
5. Wiedemann-Steiner syndrome causative splice and missense variants lead to reduction of KMT2A function. PMID: 29203834
6. SETD2 is required to maintain high H3K79 di-methylation and MLL-AF9-binding to critical target genes, such as Hoxa9. PMID: 29777171
7. One of the USP10 targets is TP53. Wildtype TP53 is usually rescued from proteasomal degradation by USP10. As most KMT2A leukemias display wildtype p53 alleles, one might argue that the disruption of an USP10 allele can be classified as a pro-oncogenic event. PMID: 30107050
8. this work highlights that MLLr AML comprises of an AML subgroup affecting younger patients with poor prognosis. The allo-HSCT in MRD-negative patients could be the best therapeutic option. PMID: 29384595
9. Myeloid Zinc Finger 1 and GA Binding Protein Co-Operate with Sox2 in Regulating the Expression of Yes-Associated Protein 1 in Cancer Cells PMID: 28905448
10. This study demonstrates a tractable approach for respecifying iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells (HSPCs) through transient expression of a single transcription factor, MLL-AF4 PMID: 29386396
11. the influence of TGFbeta/SMADs on MLL- and MLL-AF4-mediated 5-LO promoter activation PMID: 28803964
12. Chromosomal translocations involving MLL1 appear to directly perturb the regulation of multiple chromatin-associated complexes to allow inappropriate expression of developmentally regulated genes and thus drive leukemia development. [review] PMID: 28242784
13. FLT3 cell-surface expression did not vary by FLT3 mutational status, but high FLT3 expression was strongly associated with KMT2A rearrangements. Our study found that there was no prognostic significance of FLT3 cell surface expression in pediatric Acute Myeloid Leukemia PMID: 28108543
14. results indicate that KMT2A promotes melanoma growth by activating the hTERT signaling, suggesting that the KMT2A/hTERT signaling pathway may be a potential therapeutic target for melanoma. PMID: 28726783
15. A novel regulatory pathway for MLL1, which may open a new therapeutic approach to MLL-rearrangement leukaemia. PMID: 28939057
16. data confirm MLL-PTD and, to a lesser extent, FLT3-ITD as common events in +11 AML.6, 7, 8 However, the high mutation frequencies of U2AF1 and genes involved in methylation (DNMT3A, IDH2) have hitherto not been reported in +11 AML PMID: 27435003
17. It is, to our knowledge, the first case of B acute lymphoblastic leukemia with this fusion gene. At the molecular level, two rearrangements were detected using RNA sequencing juxtaposing exon 7 to exon 2 and exon 9 to intron 1-2 of the KMT2A and MAML2 genes respectively, and one rearrangement using Sanger sequencing juxtaposing exon 8 and exon 2. PMID: 28535805
18. The most common KMT2A breakpoint region was intron/exon 9 (3/8 patients), followed by intron/exon 11 and 10. PMID: 27282883
19. study describes 2 patients with Wiedemann-Steiner syndrome who presented with variable severity; findings revealed a de novo nonsense mutation, p.Gln1978*, of KMT2A in the former, and a missense mutation, p.Gly1168Asp, in the latter PMID: 27777327
20. Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement PMID: 28921816
21. Data show that expression of myeloid-lymphoid leukemia protein (MLL) fusion protein does neither influence DNA signaling nor DNA double strand breaks (DNA-DSBs) repair. PMID: 27119507
22. In this case study, we diagnosed t-MN with KMT2A rearrangement in a patient with history of B-ALL with 9p deletion and gain of X chromosome. Unusual features associated with this case are discussed PMID: 29155023
23. Identification of novel biomarkers for MLL-translocated acute myeloid leukemia. PMID: 28911906
24. Collectively, these data indicated that ATR or ATM inhibition represent potential therapeutic strategies for the treatment of AML, especially MLL-driven leukemias. PMID: 27625305
25. different cancer mutations in MLL1 lead to a loss or increase in activity, illustrating the complex and tumor-specific role of MLL1 in carcinogenesis. PMID: 28182322
26. we report two boys with novel KMT2A mutations from Chinese origin for the first time. They do not show one of the characteristic WDSTS phenotype, cubiti hypertrichosis. Instead, both of them had absent palmar proximal transverse crease. The feature was not linked to WDSTS patients previously. Our findings extend the WDSTS phenotypic spectrum. PMID: 27759909
27. Whole exome sequencing allowed identifying a previously unreported de novo KMT2A missense mutation affecting the DNA binding domain of the methyltransferase. This finding expands the clinical phenotype associated with KMT2A mutations to include immunodeficiency and epilepsy as clinically relevant features for this disorder. PMID: 27320412
28. These results define an important role for MLL1 in regulating macrophage-mediated inflammation in wound repair and identify a potential target for the treatment of chronic inflammation in diabetic wounds. PMID: 28663191
29. MLL rearrangement is associated with infant acute lymphoblastic leukemia. PMID: 27588400
30. These results reveal a cooperative transcriptional activation mechanism of AEP and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL fusion-AF4 complex and DOT1L for more effective treatment of MLL-rearranged leukemia. PMID: 28394257
31. this indicates that DOT1L function, like MLL, does not completely rely on its methyltransferase activity. Nevertheless, the small molecule DOT1L inhibition is sufficient to block the proliferation of MLL fusion-induced leukemia cells of murine and human origin PMID: 26923329
32. Studies demonstrate that histone methyl-transferase MLL1 coordinates with HIF1alpha and histone acetyltransferase p300 and regulate hypoxia-induced HOTAIR expression. The hypoxia-induced upregulation of HOTAIR expression may contribute to its roles in tumorigenesis. PMID: 28756022
33. MLL1 and MLL2 collaborate to regulate gene expression and leukemia maintenance not through redundancy, but through distinct pathways. PMID: 28609655
34. MLL1, deposits H3K4me2 at CpG-dense regions that could serve as polycomb response elements. PMID: 27447986
35. A patient was diagnosed with Wiedemann-Steiner syndrome based on identification of a novel de novo pathogenic variant in the KMT2A gene. PMID: 28359930
36. MLL gene rearrangement is associated with acute lymphocytic leukemia. PMID: 27343252
37. Our data thus extend MLL1 function to H3K4 methylation and PD-L1 transcription activation in pancreatic cancer cells. PMID: 28131992
38. KMT2A gene rearrangement is associated with acute megakaryoblastic leukemia in non-Down syndrome. PMID: 28063190
39. The data revealed the presence of a partial tandem duplication of the MLL gene as the only detectable copy number change and 11 non-silent somatic mutations, including DNMT3A R882H and NRAS G13D. All somatic lesions were present both at initial MDS/MPN-U diagnosis and at AML presentation at similar mutant allele frequencies. PMID: 27240832
40. KMT2A rearrangement is associated with B-cell lymphoblastic leukemia. PMID: 27786413
41. Loss of MLL-AF4 activity results in a reduction of H3K79me3 levels in the gene body and H3K27Ac levels at the 3' BCL-2 enhancer, revealing a novel regulatory link between these two histone marks and MLL-AF4-mediated activation of BCL-2. PMID: 27856324
42. Results revealed that double minute chromosomes in myeloid neoplasms commonly harbor MYC or MLL gene amplification and manifest as micronuclei within leukemic blasts. PMID: 27318442
43. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes. PMID: 27563068
44. miR-155 levels are correlated with MLL translocations, but that miR-155 expression is dispensable for the formation of AML and has no effect on leukemia progression. PMID: 27619068
45. MLL-ENL dysregulated the proliferative and repopulating capacity of hematopoietic stem cells. PMID: 25456127
46. This review summarizes and discusses the general mechanisms of H3K4 methylation, and how the six main enzymes from the SET/MLL family (responsible for H3K4me1/me2/me3) function in hematopoiesis and in hematologic malignancies. [review] PMID: 27796741
47. Results show that human MLL-AF9 expression in mouse long-term hematopoietic stem cells causes invasive, chemoresistant acute myeloid leukemia that expresses genes related to epithelial-mesenchymal transition. PMID: 27344946
48. Authors evaluated the expression levels of the MLL gene in AML patients. PMID: 27561414
49. Results show that MLL-AF9 reduces Id2 and increases E2-2 expression to drive and sustain leukemia stem cell potential in MLL-rearranged acute myeloid leukemia (AML). Low expression of Id2 or of an Id2 gene signature is associated with poor prognosis in not only MLL-rearranged but also t(8;21) AML patients. PMID: 27374225
50. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment. PMID: 26902498

Show More

Hide All

HGNC: 7132

OMIM: 159555

KEGG: hsa:4297

STRING: 9606.ENSP00000436786

UniGene: Hs.258855